HealthEquity Q4 2023 Earnings Report
Key Takeaways
HealthEquity reported a 15% increase in revenue to $233.8 million for the fourth quarter ended January 31, 2023. The company's net loss was $0.2 million, with non-GAAP net income of $31.3 million, or $0.37 per diluted share. Adjusted EBITDA increased by 46% to $73.6 million.
Revenue increased by 15% compared to Q4 FY22, reaching $233.8 million.
Net loss was $0.2 million, a significant improvement from the $32.8 million loss in Q4 FY22.
Non-GAAP net income was $31.3 million, compared to $17.0 million in Q4 FY22.
Adjusted EBITDA grew by 46% to $73.6 million compared to the prior year.
HealthEquity
HealthEquity
HealthEquity Revenue by Segment
Forward Guidance
For the fiscal year ending January 31, 2024, management expects revenues of $960 million to $975 million. Its outlook for net income is between $0 and $11 million, resulting in net income of $0.00 to $0.13 per diluted share. Its outlook for non-GAAP net income is between $152 million and $163 million, resulting in non-GAAP net income per diluted share of $1.74 to $1.87. Management expects Adjusted EBITDA of $320 million to $335 million.
Positive Outlook
- Revenue is expected to be between $960 million and $975 million.
- Net income is projected to be between $0 and $11 million.
- Non-GAAP net income is anticipated to be between $152 million and $163 million.
- Non-GAAP net income per diluted share is expected to be $1.74 to $1.87.
- Adjusted EBITDA is projected to be $320 million to $335 million.